Company: FTII
Filing Date: 2025-08-22
Form Type: 10-Q
Source: 0001641172-25-025250
Chunk: 63

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-08-22
Form: 10-Q
Item: Item 8
Chunk 63
---
 solely
in the capacity as sellers representative. Capitalized terms herein, unless otherwise defined, shall have the meanings ascribed to them
in the Amended Merger Agreement.

The
Amended Merger Agreement provides that the parties thereto will enter into a business combination transaction (the “Business Combination”
and together with the other transactions contemplated by the Amended Merger Agreement, the “Transactions”), pursuant to which,
among other things, (i) Longevity will consummate Target Acquisitions (as defined below) upon the terms and subject to conditions set
forth therein and pursuant to the Target Acquisition Agreements (as defined therein), and (ii) immediately following the consummation
of the Target Acquisitions, the Company will merge with and into PubCo (the “Reorganization Merger”) with PubCo as the surviving
company of the Reorganization Merger, and (iii) immediately following the consummation of the Reorganization Merger, Longevity will merge
with and into Merger Sub (the “Acquisition Merger”) with Longevity as the surviving company of the Acquisition Merger. Following
the Acquisition Merger, Longevity will be a wholly-owned subsidiary of PubCo. At the closing of the Transactions (the “Closing”),
PubCo’s common stock, par value $0.0001 per share (the “PubCo Common Stock”), is expected to list on the Nasdaq Stock
Market LLC (“Nasdaq”) under the ticker symbol “LBIO.” The date on which the Closing actually occurs is hereinafter
referred to as the “Closing Date.”

Subject
to the terms and conditions set forth in the Amended Merger Agreement, the aggregate consideration (“Merger Consideration”)
to be paid at the Closing by PubCo to the holders of Longevity common stock, par value $0.0001 per share (“Longevity Common Stock”),
will consist of a number of shares of common stock of the Company (“PubCo Common Stock”) equal to (i) (A) $100,000,000 minus
(B) the value of each outstanding vested option to purchase Longevity Common Stock that is converted into a PubCo option, in accordance
with the Amended Merger Agreement, divided by (ii) $10.00.

On
the terms and subject to the conditions set forth in the Merger Agreement,

1.
At the effective time of the Reorganization Merger (the “Reorganization Merger Effective Time”), by virtue of the Re